Treating ATTR Amyloidosis Now a Possibility as Novel Immunotherapy Enters Clinical Trial

Our researchers at the Chakrabartty lab have identified a novel immunotherapeutic drug target in the transthyretin (TTR) protein. This is a common transport protein that carries thyroxine through the blood and cerebrospinal fluid. If monomeric TTR is ever found misfolded it will not form its native homo-tetramer correctly (originally in the blood this protein native structure is comprised of four …